TNF inhibitors are also reported to increase the likelihood of hepatitis consequent to hepatitis B virus (HBV) reactivation; however, data on the specific increased risks vary between TNF inhibitors, from 12.5% to 62.5% [129,130,131]. This evidence concerns the gene TNF and hepatitis A virus infection.